|
WO2007149395A2
|
|
2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
|
|
EP2040711A2
|
|
2-oxo-1,2-dihydroquinoline derivatives, compositions, and uses thereof as antiproliferative agents
|
|
WO2007067757A2
|
|
Certain chemical entities, compositions, and methods for modulating trpv1
|
|
WO2007067711A2
|
|
Certain chemical entities, compositions, and methods for modulating trpv1
|
|
WO2007067619A2
|
|
Certain chemical entities, compositions, and methods for modulating trpv1
|
|
WO2007067710A1
|
|
Certain chemical entities, compositions, and methods for modulating trpv1
|
|
WO2007067756A2
|
|
Certain chemical entities, compositions, and methods for modulating trpv1
|
|
EP1781293A1
|
|
Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
|
|
MXPA06011046A
|
|
Certain triazole-based compounds, compositions, and uses thereof.
|
|
WO2005033102A2
|
|
Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
|
|
AU2004210665A1
|
|
Topical delivery of cosmetic agents
|
|
US2005014288A1
|
|
Motion induced electrical field stimulation
|
